
![]() |
consultation notices |
E-participation |
Quality POLICY AND COMMITMENT |
|---|
Pharmaceutical Industry Policy
![]() |
![]() |
![]() |
![]() |
|---|---|---|---|
| Axis 1 : Ensuring the continuous availability of pharmaceutical products, with a particular focus on essential medicines. Through the creation of a monitoring and surveillance device for the availability of pharmaceutical products, Continuous monitoring of import and domestic production programs, the updating of the essential medicines list, and the evaluation of import volumes according to market demand and current stock levels. |
Axis2 :Implementation of tools and a regulatory framework to ensure quality, efficiency, and safety The National Agency for Pharmaceutical Products ANPP is strengthened in human and material resources, the drug registration and medical device approval commissions, sits on the intersectoral economic committee for medicines as well as the committee of clinical experts. |
Axis 3 :
|
Axis 4 :Guaranteeing equitable and affordable access to pharmaceutical products for all citizens By expediting the approval process for pharmaceutical establishments, encouraging subcontracting, and promoting exports through the redirection of several investment projects towards local manufacturing for export purposes.The public group Saidal is benefiting from a development plan designed to establish it as a public hub ensuring national health sovereignty. |
Digital services satisfaction survey
Plateforme
![]() |
![]() |
![]() |
Plateform « تبادل – إنتاج »Online submission of digitized application files for the licensing of pharmaceutical establishments and the manufacturing of pharmaceutical products and medical devices. |
Plateform « رؤية »mproves visibility on the status of medicine stocks throughout the supply chain through: |
Plateforme « تبادل »Online submission of digitized application files for the licensing of pharmaceutical establishments, import, exploitation, and wholesale distribution of pharmaceutical products and medical devices, Or by email for approval renewals: Email : tabadol@miph.gov.dz
|
Collection of legal texts
Substances and drugs with psychotropic properties
Declarations
![]() |
![]() |
![]() |
Monthly declaration of import operations
|
Declarations of Export OperationsMonitoring of export operations for pharmaceutical products, medical devices and servicesNote N°08/MIPP/DPPP/2024 |
– Declaration of expired productsNote N° 284/MIP/DAPR/2022Legal Reference |
Diverse
![]() |
![]() |
![]() |
![]() |
Portal for declaring provisional import programs submission of provisional import programs for the 2025 financial yearNote N°467/MIPP/DAPR/2024 |
Provisional Export ProgramsSubmission of provisional export programmes for the 2024 financial yearNote N° 24/MIPP/DPDIPER/2023 |
REQUETEMEDIC
|
Portal for Technical Pharmacist Directors of Pharmaceutical EstablishmentsNote N°03/MIPP/DPDIPER/2024 |
The Pharmaceutical Industry in Algeria
How to Obtain a License for a Pharmaceutical EstablishmentThe application for a license for a pharmaceutical establishment The application for a license for a pharmaceutical establishment must be accompanied by a file containing the following documents: >> read more. |
Clinical studies
|
Export promotionAs part of the action plan of the Ministry of Pharmaceutical Industry, the promotion of exports is s a major focus for the development of the sector and its transformation from a budget-consuming sector to a wealth-creating sector. |
Pharmaceutical Establishments
|
Strategic monitoringA systematic, continuous, ethical, and legal process for collecting, analysing, processing, and disseminating information. |
Mechanism for Monitoring and Surveillance of the Availability of Pharmaceutical Products
|
Regulation and pharmaceutical activitiesRegulatory certificate ApprovalImport/Distribution/exploitation
|
File : The Serialization of MedicinesSerialization is the process of assigning unique identifiers to individual products and/or individual product packages in order to be able to readily identify and track the products and/or packages. Serialization bestows a unique, protected identity to each serialized item. |
NOMENCLATURE – 30 APRIL 2026
Form for reporting discrepancies and omissions

in the National List of Pharmaceutical Products for Human Use
Pharmaceutical establishments are requested to submit their observations regarding the nomenclature of their pharmaceutical products within one (1) month from the date of publication of the latest version of the National Nomenclature of Pharmaceutical Products for Human Use.
Videotheque
-
شريط فيدوا قصير للمعهد الجزائري للعلاج بالخلايا الجذعية و الجينية التابع للمجمع العمومي "صيدال"
-
تقرير خاص بالتلفزيون العمومي حول تخصصات المعهد الجزائري للتداوي بالخلايا الجذعية و الجينية
-
رئيس الجمهورية السيد عبد المجيد تبون يشرف على وضع حجر أساس المعهد الجزائري للتداوي بالخلايا الجذعية
-
تقرير حول الزيارة التي قام بها وزير الصحة بالنيجر لوحدة انتاج الأدوية التابعة للمجمع العمومي صيدال
-
تقرير اعلامي لقناة النهار حول إنتاج أدوية السرطان محليا..خطوة هامة في مسار تحقيق الأمن الصحي
-
مراسيم توقيع اتفاقية بين صيدال وشركة بوهرنجر إنجلهايم لتوطين تصنيع وإنتاج علاج مبتكر للتليف الرئوي
Ministry of Pharmaceutical Industry © 2021. All rights reserved.

































